失眠治療市場規模、佔有率和成長分析：按治療方法、藥物類別、給藥途徑、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球失眠治療市場價值 65 億美元，預計到 2033 年將從 2025 年的 68.6 億美元成長到 105.2 億美元，預測期（2026-2033 年）的複合年成長率為 5.5%。

失眠治療市場的主要驅動力是與老化、工作壓力增加、數位刺激以及對更安全、更有效的睡眠療法的需求相關的慢性失眠盛行率不斷上升。該市場由處方箋安眠藥、非處方藥和認知行為療法平台組成，旨在應對與未治療失眠相關的許多挑戰，包括合併症增多、生產力下降和醫療保健成本飆升。近期的一些進展，例如靶向大腦通路的創新治療方法獲得監管部門核准以及數位行為干預措施的整合，正在改變失眠的治療方法。此外，人工智慧技術在藥物研發中的應用正在加速標靶識別、改善分子設計和實現個人化治療，從而促進市場成長，提高保險公司和臨床醫生的接受度，同時簡化監管流程並刺激研發投資。

全球失眠治療市場的成長要素

慢性及急性睡眠障礙的日益普遍，導致對有效失眠治療方法的需求不斷成長，促使醫療保健機構更加重視這些疾病的管理。隨著受影響人數的增加，製藥公司面臨巨大的壓力，需要加強對創新治療方法研發和商業化的投入。醫療保健專業人員和保險公司也越來越積極地尋求改善睡眠品質和日間表現的新方案。為此，製造商正在拓展產品平臺和行銷活動，以滿足這些未被滿足的需求，從而加速新產品的上市，並擴大失眠治療的潛在市場。

全球失眠治療市場的限制因素

全球失眠治療市場面臨許多限制因素，其中最主要的監管要求是長期安全性、潛在濫用風險和正確的標籤說明。這些嚴格的要求會延長研發週期，增加失眠治療公司的成本，往往會阻礙小規模的研發公司繼續推動候選藥物的研發。這種出於對大量臨床證據和上市後研究的需求而採取的謹慎商業化策略，往往會延緩創新產品的上市。因此，人們傾向於優先考慮漸進式改進，而非追求突破性的治療方法創新，最終限制了市場上可供選擇的治療方法方案。

全球失眠治療市場趨勢

全球失眠治療市場正呈現出顯著的數位化療法整合趨勢，其特徵是採用基於軟體的睡眠介入和行動認知行為療法工具。這種轉變正在改變傳統的治療模式，促進持續的患者監測、遠端劑量調整，並在傳統臨床環境之外加強藥物依從性支持。製藥公司和科技公司之間的合作正在推動一種結合行為改變和藥物治療的綜合護理方法，最終實現更個人化的護理和更好的長期患者療效。隨著支付方和醫療服務提供者越來越重視與功能恢復和生活品質 (QOL) 相關的基於價值的報銷，開發能夠整合臨床監管和方便用戶使用型互動策略的互通平台變得日益重要。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球失眠治療市場規模：依治療類型分類

• 處方藥
• 非處方藥
• 行為療法與認知療法
• 數位療法（CBT-I平台）

全球失眠治療市場規模：依藥物類別分類

• 苯二氮平類藥物
• 非苯二氮平類催眠藥
• 褪黑素受體促效劑
• Orexin受體拮抗劑
• 抗憂鬱症
• 其他

全球失眠治療藥物市場規模：依給藥途徑分類

• 口服
• 經皮
• 其他

全球失眠治療市場規模：按應用領域分類

• 慢性失眠
• 急性失眠
• 合併失眠症

全球失眠治療市場規模：依最終用戶分類

• 醫院
• 專科診所
• 居家醫療環境
• 其他

全球失眠治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球失眠治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Eisai Co., Ltd.
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Idorsia Pharmaceuticals Ltd.
• Vanda Pharmaceuticals Inc.
• Currax Pharmaceuticals LLC
• Neurim Pharmaceuticals Ltd.
• Purdue Pharma LP
• Astellas Pharma Inc.
• Viatris Inc.
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Lupin Limited
• Pear Therapeutics Inc.

結論與建議

Global Insomnia Therapeutics Market size was valued at USD 6.5 Billion in 2024 and is poised to grow from USD 6.86 Billion in 2025 to USD 10.52 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The insomnia therapeutics market is primarily driven by the demand for safer and more effective sleep treatments, fueled by the increasing prevalence of chronic insomnia linked to aging populations, heightened work stress, and digital stimulation. Comprising prescription hypnotics, over-the-counter remedies, and cognitive behavioral therapy platforms, this market addresses significant issues associated with untreated insomnia, such as increased comorbidity, decreased productivity, and higher healthcare costs. Recent advancements, including regulatory approvals for innovative therapies targeting brain pathways and the integration of digital behavioral interventions, are reshaping treatment approaches. Additionally, the incorporation of AI technologies in drug development is facilitating faster target identification, enhancing molecule design, and personalizing therapies, supporting market growth and adoption among payers and clinicians while streamlining regulatory processes and encouraging R&D investments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insomnia Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insomnia Therapeutics Market Segments Analysis

Global insomnia therapeutics market is segmented by treatment type, drug class, route of administration, application, end-user, distribution channel and region. Based on treatment type, the market is segmented into Prescription Medications, Over-the-Counter (OTC) Drugs, Behavioural & Cognitive Therapies and Digital Therapeutics (CBT-I platforms). Based on drug class, the market is segmented into Benzodiazepines, Non-benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, Antidepressants and Others. Based on route of administration, the market is segmented into Oral, Transdermal and Others. Based on application, the market is segmented into Chronic Insomnia, Acute Insomnia and Comorbid Insomnia. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare Settings and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insomnia Therapeutics Market

The rising prevalence of chronic and acute sleep disorders has intensified the demand for effective insomnia treatments, leading healthcare providers to focus more on managing these conditions. As the number of affected individuals grows, there is a significant push for pharmaceutical companies to invest in the research, development, and commercialization of innovative therapies. Healthcare professionals and insurers are increasingly open to exploring new solutions that enhance sleep quality and daytime performance. In response, manufacturers are broadening their product pipelines and marketing initiatives to address these unmet needs, thus speeding up the introduction of new products and expanding the potential market for insomnia therapeutics.

Restraints in the Global Insomnia Therapeutics Market

The Global Insomnia Therapeutics market faces significant constraints due to complex regulatory demands that focus on long-term safety, potential for abuse, and appropriate labeling. Such stringent requirements can elongate development timelines and escalate costs for companies dedicated to insomnia treatments, often discouraging smaller developers from advancing their candidates. This cautious approach to commercialization, driven by the necessity for extensive clinical evidence and post-marketing commitments, tends to slow the introduction of innovative products. Consequently, there is a tendency to prioritize incremental advancements rather than pursuing groundbreaking therapeutic innovations, which ultimately restricts the variety of available treatment options in the market.

Market Trends of the Global Insomnia Therapeutics Market

The Global Insomnia Therapeutics market is witnessing a significant trend towards the integration of digital therapeutics, characterized by the adoption of software-based sleep interventions and mobile cognitive behavioral therapy tools. This shift is transforming traditional care models by facilitating continuous patient monitoring, enabling remote titration of treatments, and enhancing adherence support outside conventional clinical settings. Collaborations between pharmaceutical and technology firms are fostering integrated care approaches that combine behavioral modifications with pharmacological solutions, ultimately leading to improved individualized care and long-term patient outcomes. As payers and providers increasingly prioritize value-based reimbursement linked to functional recovery and quality of life, there is a growing emphasis on developing interoperable platforms that merge clinical oversight with user-friendly engagement strategies.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Insomnia Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Prescription Medications
• Over-the-Counter (OTC) Drugs
• Behavioural & Cognitive Therapies
• Digital Therapeutics (CBT-I platforms)

Global Insomnia Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Benzodiazepines
• Non-benzodiazepine Hypnotics
• Melatonin Receptor Agonists
• Orexin Receptor Antagonists
• Antidepressants
• Others

Global Insomnia Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Transdermal
• Others

Global Insomnia Therapeutics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Chronic Insomnia
• Acute Insomnia
• Comorbid Insomnia

Global Insomnia Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others

Global Insomnia Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Insomnia Therapeutics Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Application, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Currax Pharmaceuticals LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurim Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma L.P.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pear Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations